When to Use Epitope Scout vs. a Structural Biologist

If you are running a de novo binder design campaign, the single most consequential decision is which surface on your target to direct the design against. In a well-resourced biopharma pipeline, this decision is made by a structural biologist looking at the target in PyMOL, cross-referencing the PPI literature, and integrating experimental context. In a small team without that expertise, it is often made by looking at the structure in a browser viewer and picking a spot that “looks nice.” The gap between those two processes is where most first-time binder campaigns lose their budget.

Epitope Scout is designed to automate the reproducible, literature-backed parts of that decision. It is not a replacement for a structural biologist on every project — but it is enough for most projects, and it is strictly better than eyeballing.

This post is about when it is enough and when it is not.

What Epitope Scout Does

Epitope Scout takes a target structure (PDB or mmCIF, experimental or AlphaFold) and returns a ranked list of candidate surface epitope patches, each scored on a composite of five structural properties:

Hydrophobic exposure (weighted 30%)
Structural order — beta-strands and helices vs loops (20%)
Rigidity — B-factor or pLDDT (20%)
Surface accessibility (15%)
Hot-spot residue density — Trp, Tyr, Arg, Phe (15%)

These are the five criteria most consistently identified in the protein-protein interaction literature as predictive of bindable surface. The scoring is fully automated, runs in minutes on a standard PDB file, and produces an output ready to pass directly into RFdiffusion as a hotspot specification.

What Epitope Scout also adds beyond the composite score:

PPI interface detection. Flags patches that overlap with natural protein-protein interaction interfaces present in the structure.
Known binder lookup. Queries SAbDab and RCSB for existing antibody and nanobody structures against the target, showing which residues those binders contact.
Quality flags. Non-scoring annotations for potential concerns: loop-only anchors, all-polar patches, glycan proximity, high local flexibility, electrostatic asymmetry.

This is the kind of triage a structural biologist would do in the first 30-60 minutes of looking at a target. Automating it means it happens consistently, reproducibly, and before any compute budget is spent.

When Epitope Scout Is Enough

For most first-time binder design campaigns, Epitope Scout alone is sufficient for hotspot selection. Specifically:

Soluble extracellular targets with a known or well-predicted structure. The five scoring criteria are well-validated for this class of target.
Targets where the downstream binder just needs to bind, not to compete with a specific partner. If you are generating an affinity reagent, a tool binder, or a research-grade ligand for a detection assay, a high-scoring epitope patch is usually a valid choice regardless of its biological role.
Targets with existing structural data and a literature base. The PPI interface detection and known binder lookup surface the context that would take a human several hours to compile manually.
Teams without in-house structural biology expertise. In this case the alternative is not a structural biologist — it is an untrained picker. Epitope Scout is strictly better.
Early-stage scoping. Before committing to a target, Epitope Scout can tell you in five minutes whether any part of the target is even plausibly bindable. That is useful triage.

When You Need a Structural Biologist in the Loop

There are several classes of target and project where automated scoring alone is not sufficient, and a structural biologist (or a protein engineer with deep target-area expertise) needs to make the call.

Allosteric or mechanism-dependent binding. If the goal is not just to bind the target but to inhibit it, activate it, or modulate a specific conformation, the epitope choice is constrained by mechanism. Epitope Scout will rank patches by bindability; it does not know that a specific surface is the catalytic site, the dimerization interface, or the allosteric switch. A structural biologist familiar with the target family needs to translate “I want to block substrate entry” into a residue-level selection.

Conformational ensembles and cryptic pockets. If the target has multiple functionally relevant conformations (active/inactive states, open/closed forms, induced-fit pockets), picking an epitope from a single static structure can be misleading. A structural biologist familiar with the target’s conformational landscape is needed to decide which state to design against.

Membrane proteins and complex topologies. GPCRs, transporters, and multi-pass membrane proteins have accessibility constraints that Epitope Scout does not fully model. A human with domain expertise needs to decide whether a patch is exposed in the membrane context, which detergent or nanodisc conditions will preserve it, and how the display system will present it.

Targets with known failed campaigns. If the target has a history of failed binder attempts in the literature, the specific reasons for failure matter. Sometimes the target is fundamentally hard (glycan shield, fast conformational dynamics, low surface hydrophobicity); sometimes prior attempts targeted the wrong surface. A structural biologist can read that literature and reconcile it against a new design strategy.

Therapeutic epitope selection. For clinical or preclinical antibody programs, epitope choice has to account for developability, immunogenicity risk, cross-reactivity with homologous human proteins, and patent freedom-to-operate. None of that is structural — it is a strategic decision that an automated tool will not make for you.

Post-translational modification dependency. If the native binding partners of the target recognize a phosphorylated, glycosylated, acetylated, or otherwise modified version of the surface, the PTM state of your recombinant target during display matters. A structural biologist or target-area expert needs to confirm that the displayed target carries (or lacks) the relevant modifications.

A Checklist for Your Target

To decide which side you are on, ask:

Is the target soluble, extracellular, and structurally well-defined? → Epitope Scout is likely enough.
Is the target a GPCR, ion channel, transporter, or multi-pass membrane protein? → Get a structural biologist involved.
Is mechanism (inhibition, activation, allostery) a required property of the binder? → Get a structural biologist involved.
Is the target heavily glycosylated or PTM-dependent? → Get a structural biologist involved.
Is this a first-in-class binder against a target with no prior structural validation? → Epitope Scout for initial triage, then human review before synthesis.
Is this an affinity reagent, detection tool, or research-grade binder where bindability alone is the criterion? → Epitope Scout is almost certainly enough.
Are you preparing a campaign for a therapeutic program with IP, immunogenicity, or clinical considerations? → Get a structural biologist, a regulatory consultant, and an IP attorney involved. None of those decisions are automatable.

The Honest Answer

For most first binder campaigns that small biotech and academic teams run, Epitope Scout is the right tool and a structural biologist is not available anyway. The practical upgrade path is:

Run Epitope Scout on your target. Get the ranked patches and the quality flags.
If everything looks green — high-scoring patches, no red-flag quality issues, clear separation between top and bottom patches — move into a binder design campaign.
If the quality flags raise real concerns (loop-only anchors, glycan proximity, PTM dependency suspected, no clear winning patch), that is the signal to bring in a structural biologist for a one-off consultation before committing compute and synthesis budget.

The goal is not to automate the structural biology. It is to automate the parts that should be automated, so that when you bring in a human expert, their time goes to the decisions that actually need human judgment.

If you want to try this on your own target: Epitope Scout is free to use, no credit card, no NDA. If you decide to move into a campaign afterward, the Binder Pilot and AI Binder Sprint programs both accept Epitope Scout output directly as the hotspot specification.

Epitope Scout: Free surface epitope identification at scout.ranomics.com.
AI Binder Sprint: Full structural review + de novo binder design when Epitope Scout alone isn’t enough.